Skip to content
etf.net

BIB vs ROM

ProShares Ultra Nasdaq Biotechnology

BIBBNasdaq

ProShares Ultra Technology

ROMANYSE Arca

Overlap

Expense ratio

ROM −0.02pt a year

BIB0.95%ROM0.93%

Avg volume · 30D

ROM 4.5×the volume

BIB10.5KROM47.7K

10Y return · a year

ROM +24.0pt

BIB+12.6%ROM+36.6%

BIB vs ROM Performance

Oct 29, 2021 – Oct 30, 2026

+36.3%BIB+126.1%ROM

Oct 29, 2021 to Oct 30, 2026. BIB +36.3%. ROM +126.1%. Use the arrow keys to read each point.−50%0%200%Oct 2021Apr 2024Oct 2026
Expense ratio
BIB 0.95%
ROM 0.93%, better
Fund size
BIB $104M
ROM $1.15B
1Y total return
BIB +68.9%, better
ROM +26.5%
Yield (12M)
BIB 0.19%, better
ROM 0.03%
Holdings
BIB 247
ROM 85
Avg volume (30D)
BIB 10.5K sh
ROM 47.7K sh, better
NAV per share
BIB $120.62
ROM $132.18
52W range

ETF.net Grade

BIB: Cost 51, Risk 70, Mission not scored, Tradability 84, Holdings 60, Durability 75. ROM: Cost 70, Risk 56, Mission not scored, Tradability 88, Holdings not scored, Durability 81.
Pillar letters and Scores for BIB, ROM, with each pillar’s weight
PillarBIBROM
Cost30% weightC51A70Higher
Mission25% weightNot scoredNot scored
Risk15% weightA70HigherB56
Tradability15% weightA84A88Higher
Holdings10% weightB60Not scored
Durability5% weightA75A81Higher

Rank among Leveraged Long (2x & Other) funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. BIB and ROM are both graded against the same 95 Leveraged Long (2x & Other) funds, so their Grades compare head to head.

Leveraged Long (2x & Other)⁠

Category · 95 funds
See all 95 ›

ROM ranks 3rd and BIB 8th of 95 funds in the Leveraged Long (2x & Other) Category.

  1. Rank 1AQLDProShares Ultra QQQScore 77
  2. Rank 2AUYGProShares Ultra FinancialsScore 74
  3. Rank 3AROMProShares Ultra TechnologyScore 71
  4. Rank 4BDDMProShares Ultra Dow30Score 69
  5. Rank 7BUJBProShares Ultra High YieldScore 65
  6. Rank 8BBIBProShares Ultra Nasdaq BiotechnologyScore 64
  7. Rank 9BMVVProShares Ultra MidCap400Score 63

Our read on each fund

ETF.net Research

BIBBProShares Ultra Nasdaq Biotechnology

ROMAProShares Ultra Technology

In short

BIB Biotech with the dial at 2x, not 3x. Since 2010 BIB has aimed at twice the daily move of the Nasdaq Biotechnology Index, a modified cap-weighted set of Nasdaq-listed biotech and pharma names, reset fresh every single day.

ROM The original 2x tech trade. Since 2007, ROM has aimed at twice the daily move of the S&P 500's technology sector: a double dose in a category now stacked with triples.

Stated mandate

BIB The Fund seeks daily investment results, before fees and expenses, that correspond to two times the daily performance of the Nasdaq Biotechnology Index.

ROM ROM seeks daily investment results, before fees and expenses, corresponding to twice the daily performance of the S&P Technology Select Sector SM Index.

Why people hold it

  • BIB Aims for two times the daily move of the Nasdaq Biotechnology Index. Magnified biotech exposure through one ticker in a regular brokerage account, no margin agreement needed.proshares.com
  • The benchmark dates to 1993: Nasdaq-listed biotech and pharma, modified cap-weighted, roughly 300 stocks. Industry-wide exposure, not a handful of lottery tickets.nasdaqomx.comnasdaqomx.com 2
  • 0.95% net of a waiver through September 30, 2027, against a 1.17% gross. Near the category median and level with ProShares stablemate DDM at 0.95%.
  • Live since 2010 through several biotech boom-and-bust cycles, and it stands among the stronger implementations in a crowded leveraged-bull field.
  • ROM Two times, not three. A 2x daily target means smaller swings and less compounding drag than a 3x fund chasing the same sector.sec.gov
  • Live since January 2007, so it has run through the 2008 crash and the full tech cycle since. Long mileage is rare in geared funds.
  • 0.93% a year, flat, with no waiver propping it up. Peer QLD runs 0.89%, but only net of a waiver through September 30, 2027.
  • One of the strongest implementations in the leveraged-bull pack, from an issuer that has run geared funds since the category's early days.proshares.com

Worth knowing

  • BIB Daily reset. Hold past one day and compounding takes over: returns can differ in amount, and even direction, from 2x the index over that stretch.proshares.com
  • One industry, doubled. Trial readouts and FDA decisions move biotech hard, and this fund is built to amplify those days in both directions.proshares.com
  • Among the lighter-traded, smaller funds in its category, so spreads and order size matter more here than with the headline leveraged names.
  • ROM The 2x target resets at each close, so results over weeks or months depend on the path the sector takes, not just where it ends up.sec.govproshares.com
  • Trades thinner than the category's headline names, so spreads and limit orders matter, especially in size.
  • About 80 tech names from the S&P 500. That is one concentrated sector bet, doubled, in both directions.

Full BIB profile⁠

Full ROM profile⁠

BIB vs ROM Holdings

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

BIB vs ROM Cost

Overpaying BIB vs ROM

$330

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BIB 0.95%

    $17,869

  • ROM 0.93%

    $17,539

$10,000
30 years

Cost over time

  • BIB 0.95%
  • ROM 0.93%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K$20K051015202530BIB $17,869ROM $17,539

Year by year

YearBIBROMOverpaying
10$1,678$1,644$34
20$6,322$6,199$123
30$17,869$17,539$330

Expense ratio

  • 0.95%BIB
  • 0.93%ROM, cheaper
  • Middle half of Leveraged Long (2x & Other) funds
  • Median 0.95%

ROM 29th cheapest of 95 funds

BIB 32nd cheapest of 95 funds

BIB vs ROM Dividends

Last 12 months to Oct 30, 2026
Yield (12M)
BIB 0.19%, better
ROM 0.03%
Payout (12M)
BIB $0.22
ROM $0.04
Last payment
BIB $0.08
ROM $0.02
Ex-dividend
BIB Sep 23, 2026
ROM Mar 25, 2026
Paid on
BIB Sep 29, 2026
ROM Mar 31, 2026
Frequency
BIB Twice a year
ROM Quarterly

Distribution history

Per share, 2017 to 2026, same scale for both

BIBTwice a year · 12 paymentsAll BIB payments⁠
One bar per payment. 12 payments from 2017 to 2026 YTD. Dec 22, 2022 $0.02; Dec 20, 2023 $0.04; Mar 20, 2024 $0.04; Jun 26, 2024 $0.26; Sep 25, 2024 $0.15; Dec 23, 2024 $0.40; Mar 26, 2025 $0.13; Jun 25, 2025 $0.17; Sep 24, 2025 $0.18; Dec 24, 2025 $0.13; Mar 25, 2026 $0.0071; Sep 23, 2026 $0.08. Use the arrow keys to read each point.$0$0.252017202020232026YTD
ROMQuarterly · 19 paymentsAll ROM payments⁠
One bar per payment. 19 payments from 2017 to 2026 YTD. Mar 22, 2017 $0.0015; Dec 26, 2017 $0.0075; Mar 21, 2018 $0.0064; Jun 20, 2018 $0.006; Dec 26, 2018 $0.02; Mar 20, 2019 $0.01; Jun 25, 2019 $0.0043; Dec 24, 2019 $0.01; Mar 25, 2020 $0.02; Dec 20, 2023 $0.0042; Mar 20, 2024 $0.01; Jun 26, 2024 $0.04; Sep 25, 2024 $0.06; Dec 23, 2024 $0.03; Mar 26, 2025 $0.02; Jun 25, 2025 $0.14; Sep 24, 2025 $0.05; Dec 24, 2025 $0.02; Mar 25, 2026 $0.02. Use the arrow keys to read each point.$0$0.252017202020232026YTD

BIB vs ROM Risk

Fall from peak · 5 years

  • BIB
  • ROM
Oct 29, 2021 to Oct 30, 2026. Worst fall: ROM −67.6% · Nov 2022. Use the arrow keys to read each point.−60%−40%−20%0%Oct 2021Apr 2024Oct 2026

Risk facts

VolatilityStd dev, 3 years
BIB 33.9%, betterROM 49.3%
Return per unit of riskSharpe ratio, 3 years
BIB 1.12, betterROM 0.97
Worst fallMax drawdown, 5 years
BIB −61.8%, betterROM −67.6%
Market sensitivityBeta, 5 years
BIB 1.20ROM 3.09

Popular comparisons

  • BIBBvsQLDA

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra QQQ

    Expense ratio
    0.95% · 0.89%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • ROMAvsQLDA

    ProShares Ultra Technology · ProShares Ultra QQQ

    Expense ratio
    0.93% · 0.89%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BIBBvsUYGA

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra Financials

    Expense ratio
    0.95% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • ROMAvsUYGA

    ProShares Ultra Technology · ProShares Ultra Financials

    Expense ratio
    0.93% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BIBBvsDDMB

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra Dow30

    Expense ratio
    0.95% · 0.95%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • ROMAvsDDMB

    ProShares Ultra Technology · ProShares Ultra Dow30

    Expense ratio
    0.93% · 0.95%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.